Physician profile
Joshua Peter Alpers
NPI 1801926100
$623,078.09
in general payments reported to CMS, 2019-2025
56 companies · $205K in 2025
The $205K reported for 2025 was more than what 99% of Neuromuscular Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $530).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $16K · 2021: $12K · 2022: $86K · 2023: $143K · 2024: $149K · 2025: $205K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $334K · Consulting Fee: $91K · Travel and Lodging: $57K · Food and Beverage: $15K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $333,929.00 |
| Consulting Fee | $90,508.78 |
| Travel and Lodging | $57,190.33 |
| Food and Beverage | $15,124.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $304,219.93 | 2019-2025 | Ultomiris, Soliris |
| Argenx US, INC. | $146,057.80 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Ucb, INC. | $124,369.67 | 2020-2025 | Rystiggo, Zilbrysq, Fintepla |
| Janssen Biotech, INC. | $19,367.04 | 2024-2025 | Tremfya |
| Tanabe Pharma America, INC. | $10,879.36 | 2019-2025 | Radicava |
| Csl Behring | $6,435.86 | 2019-2024 | Hizentra |
| Amgen INC. | $2,261.63 | 2024-2025 | Uplizna, Aimovig |
| Genentech USA, INC. | $2,200.84 | 2021-2024 | Evrysdi, Ocrevus |
| Abbvie INC. | $1,388.67 | 2019-2025 | Botox, Qulipta, Ubrelvy |
| Mdd US Operations, LLC | $776.02 | 2023-2025 | Gocovri, Apokyn, Gocovri |
| Teva Pharmaceuticals USA, INC. | $708.62 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Edw Pharma, INC. | $404.61 | 2019-2023 | Tiglutik |
| Lundbeck LLC | $343.62 | 2019-2025 | Vyepti |
| Alnylam Pharmaceuticals INC. | $242.54 | 2022-2025 | Amvuttra |
| Pfizer INC. | $225.02 | 2022-2025 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Alpers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.